argenx SE (ARGX)

Market Cap	48.50B +45.4%
Revenue (ttm)	4.24B +88.4%
Net Income	1.29B +55.1%
EPS	19.57 +53.1%
Shares Out	62.06M
PE Ratio	37.54
Forward PE	28.18
Dividend	n/a
Ex-Dividend Date	n/a

Volume	339,092
Open	785.28
Previous Close	787.95
Day's Range	778.20 - 787.08
52-Week Range	510.06 - 934.62
Beta	-0.09
Analysts	Strong Buy
Price Target	1,008.56 (+29.26%)
Earnings Date	May 7, 2026

About ARGX

argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. The company offers VYVGART for the treatment of gMG and immune thrombocytopenia (ITP), and VYVGART HYTRULO for the treatment of gMG and chronic inflammatory demyelinating polyneuropathy (CIDP). It also develops efgartigimod for the treatment of seronegative gMG, ocular myasthenia gravis (MG), primary ITP, grave’s disease, myositis, Sjögren’s disease, system...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: May 18, 2017
• Employees: 1,863
• Stock Exchange: NASDAQ
• Ticker Symbol: ARGX
• Website: https://argenx.com

Financial Performance

In 2025, argenx SE's revenue was $4.24 billion, an increase of 88.44% compared to the previous year's $2.25 billion. Earnings were $1.29 billion, an increase of 55.10%.

Analyst Summary

According to 19 analysts, the average rating for ARGX stock is "Strong Buy." The 12-month stock price target is $1,008.56, which is an increase of 29.26% from the latest price.

Price Target

$1,008.56

(29.26% upside)

Analyst Consensus: Strong Buy